Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Core Insights - Aligos Therapeutics, Inc. announced positive data from eight presentations at the AASLD The Liver Meeting® 2025, showcasing the potential of their therapy for liver and viral diseases [1][2]. Pevifoscorvir Sodium Data - Pevifoscorvir sodium demonstrated significant efficacy in treating chronic hepatitis B virus (HBV) infection, with 75% of HBeAg+ subjects maintaining HBV DNA levels below the lower limit of quantification (LLOQ) after transitioning to nucleos(t)ide analog (NA) monotherapy [2][6]. - In HBeAg- subjects, 100% maintained HBV DNA < LLOQ during the follow-up period, indicating strong viral suppression [2][5]. - The therapy showed a rapid and durable reduction in HBV DNA levels, with 60% of HBeAg+ subjects achieving HBV DNA < LLOQ by Week 48, increasing to 100% by Week 96 [4][6]. Mechanism of Action - Preclinical data indicated that ALG-001075, the active component of pevifoscorvir sodium, can prevent cccDNA formation and HBV DNA integration, suggesting a novel mechanism of action [3][8]. - The therapy's ability to reduce HBV antigens and RNA during NA therapy indicates its potential to inhibit cccDNA establishment [6][7]. Presentation Highlights - The oral presentation by Professor Man-Fung Yuen emphasized the first-in-class potential of pevifoscorvir sodium, reinforcing its impact on the HBV lifecycle [9]. - Multiple poster presentations showcased ongoing research and innovation in HBV treatment, including differentiation of capsid assembly modulators and their effects on HBV core protein [10][11]. Future Directions - The company is advancing the Phase 2 B-SUPREME study and is optimistic about the progress of its HBV ASO program, which has shown promising preclinical results [7][8].